The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Lenalidomide for smoldering myeloma
Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, gives an insight on the results presented at ASCO 2019 from the largest randomized controlled study in smoldering multiple myeloma looking at lenalidomide vs. observation ECOG-E3A06 (NCT01169337), and comparing these results with those from a past Spanish trial. Talking at the Controversies in Multiple Myeloma (COMy) 2019 meeting held in Paris, France, Dr Rajkumar highlights the positive results that they have found.
